Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Undergraduate School

Massachusetts Institute of Technology

2007, Cambridge, MA

Medical School

University if Massachusetts Medical School

2011, Worcester, MA

Residency

NY Presbyterian Hospital/Weill Cornell Medical School

2018, New York, NY

Fellowship

Schepens Eye Research Institute/Mass Eye and Ear Boston

2014, Boston, MA

Certifications

  • American Board of Ophthalmology (General)

Professional History

  Dr. Dohlman is a clinician-scientist who specializes in the medical and surgical management of corneal and external eye diseases. Dr. Dohlman earned his BS degree from MIT and MD from the University of Massachusetts Medical School. He then completed a Postdoctoral Research Fellowship in Corneal Immunology and Corneal Transplantation Immunology at the Schepens Eye Research Institute of Mass. Eye and Ear. He went on to complete his residency training in ophthalmology at New York Presbyterian/Weill Cornell Medical College, after which he returned to Mass. Eye and Ear for further subspecialty training as an Advanced Two-Year Combined Clinical and Research Fellow in Cornea, Refractive Surgery, and External Disease. Dr. Dohlman cares for pediatric and adult patients with corneal disease and conducts basic science and clinical research in the areas of corneal immunology and inflammation, corneal transplantation immunology, corneal fibrosis/scarring and ocular surface disease.
 

Publications

  1. Subconjunctival Adalimumab for Noninfectious Uveitis: A Prospective Pilot Study. Ocul Immunol Inflamm. 2025 May 27; 1-3. View Abstract

  2. Neurotrophic Keratopathy in Pediatric Population: An IRIS® Registry Report. Ophthalmology. 2025 Apr 25. View Abstract

  3. Visual Outcomes of Limbal Stem Cell Transplantation in the IRIS® Registry. Ophthalmology. 2025 Apr 12. View Abstract

  4. Optical Coherence Tomography Angiography in Patients With the Boston Keratoprosthesis Type 1. Cornea. 2025 Jan 14. View Abstract

  5. Immunology in corneal transplantation-From homeostasis to graft rejection. Transplant Rev (Orlando). 2025 Apr; 39(2):100909. View Abstract

  6. State-of-the-Art Review: Ocular Infections. Clin Infect Dis. 2024 Nov 22; 79(5):e48-e64. View Abstract

  7. Executive Summary: State-of-the-Art Review: Ocular Infections. Clin Infect Dis. 2024 Nov 22; 79(5):1125-1126. View Abstract

  8. Assessment of Corneal Graft Outcomes in a Murine Model of Endothelial Keratoplasty. J Clin Med. 2024 Aug 24; 13(17). View Abstract

  9. Neuropeptide alpha-Melanocyte stimulating hormone preserves corneal endothelial morphology in a murine model of Fuchs dystrophy. Sci Rep. 2024 08 14; 14(1):18842. View Abstract

  10. Complications After Pediatric Penetrating Keratoplasty: An IRIS Registry Study. Cornea. 2024 Dec 01; 43(12):1555-1559. View Abstract

  11. Potential applications of mesenchymal stem cells in ocular surface immune-mediated disorders. Surv Ophthalmol. 2025 May-Jun; 70(3):467-479. View Abstract

  12. Corneal Opacity in the United States: An American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) Study. Ophthalmology. 2025 Jan; 132(1):52-61. View Abstract

  13. Immunopathological mechanisms and clinical manifestations of ocular graft-versus-host disease following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024 Aug; 59(8):1049-1056. View Abstract

  14. Ocular Blast Injuries in Military and Civilian Mass-casualty Settings. Int Ophthalmol Clin. 2024 Apr 01; 64(2):209-220. View Abstract

  15. Myeloid-derived suppressor cells promote allograft survival by suppressing regulatory T cell dysfunction in high-risk corneal transplantation. Am J Transplant. 2024 Sep; 24(9):1597-1609. View Abstract

  16. Visual outcomes of children undergoing penetrating keratoplasty in the US. Ocul Surf. 2024 Apr; 32:219-221. View Abstract

  17. Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation. Ophthalmol Sci. 2024 Jul-Aug; 4(4):100492. View Abstract

  18. Therapeutic Effects of Stimulating the Melanocortin Pathway in Regulating Ocular Inflammation and Cell Death. Biomolecules. 2024 Jan 31; 14(2). View Abstract

  19. Effector T Cells Promote Fibrosis in Corneal Transplantation Failure. Invest Ophthalmol Vis Sci. 2024 Jan 02; 65(1):40. View Abstract

  20. Concurrence of Ocular Cicatricial Pemphigoid in Chronic Ocular Graft-Versus-Host Disease. Cornea. 2024 Mar 01; 43(3):387-390. View Abstract

  21. The Neuropeptide a-Melanocyte-Stimulating Hormone Prevents Persistent Corneal Edema following Injury. Am J Pathol. 2024 01; 194(1):150-164. View Abstract

  22. The prophylactic value of TNF-a inhibitors against retinal cell apoptosis and optic nerve axon loss after corneal surgery or trauma. Acta Ophthalmol. 2024 May; 102(3):e381-e394. View Abstract

  23. Insights into mustard gas keratopathy- characterizing corneal layer-specific changes in mice exposed to nitrogen mustard. Exp Eye Res. 2023 11; 236:109657. View Abstract

  24. Temporal keratoconus in a pediatric patient. Am J Ophthalmol Case Rep. 2023 Dec; 32:101900. View Abstract

  25. The impact of donor diabetes on corneal transplant immunity. Am J Transplant. 2023 09; 23(9):1345-1358. View Abstract

  26. Insights into mustard gas keratopathy: Characterizing corneal layer-specific changes in mice exposed to nitrogen mustard. Exp Eye Res. 2023 May 02; 109495. View Abstract

  27. Eye Swelling and Decreased Vision in a Patient With Autism. J Neuroophthalmol. 2023 06 01; 43(2):e63. View Abstract

  28. Conventional type I migratory CD103+ dendritic cells are required for corneal allograft survival. Mucosal Immunol. 2023 Oct; 16(5):711-726. View Abstract

  29. Descemet Stripping Only Technique for Corneal Endothelial Damage in Mice. Cornea. 2023 Apr 01; 42(4):470-475. View Abstract

  30. Penetrating Keratoplasty: Indications and Graft Survival by Geographic Region. Semin Ophthalmol. 2023 Jan; 38(1):31-43. View Abstract

  31. Ocular pain in ocular graft-versus-host disease patients with neurotrophic keratopathy. Ocul Surf. 2022 10; 26:142-147. View Abstract

  32. Prevalence of neurotrophic keratopathy in patients with chronic ocular graft-versus-host disease. Ocul Surf. 2022 10; 26:13-18. View Abstract

  33. Modulating the tachykinin: Role of substance P and neurokinin receptor expression in ocular surface disorders. Ocul Surf. 2022 07; 25:142-153. View Abstract

  34. A Novel Murine Model of Endothelial Keratoplasty. Cornea. 2023 Feb 01; 42(2):224-231. View Abstract

  35. Bevacizumab in High-Risk Corneal Transplantation: A Pilot Multicenter Prospective Randomized Control Trial. Ophthalmology. 2022 08; 129(8):865-879. View Abstract

  36. Immune regulation of the ocular surface. Exp Eye Res. 2022 05; 218:109007. View Abstract

  37. Novel adaptation of a running suture technique in a mouse model of corneal transplantation. J Biol Methods. 2021; 8(4):e156. View Abstract

  38. Limbal Stem Cell Deficiency Associated With Herpes Keratitis. Cornea. 2021 Aug 01; 40(8):967-971. View Abstract

  39. A Review of Ocular Graft-versus-Host Disease: Pathophysiology, Clinical Presentation and Management. Ocul Immunol Inflamm. 2021 Aug 18; 29(6):1190-1199. View Abstract

  40. Prevalence and Risk Factors Associated With Corneal Perforation in Chronic Ocular Graft-Versus-Host-Disease. Cornea. 2021 Jul 01; 40(7):877-882. View Abstract

  41. Ocular redness - I: Etiology, pathogenesis, and assessment of conjunctival hyperemia. Ocul Surf. 2021 07; 21:134-144. View Abstract

  42. Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia. Ocul Surf. 2021 07; 21:66-77. View Abstract

  43. Advances in the Medical Management of Neurotrophic Keratitis. Semin Ophthalmol. 2021 May 19; 36(4):335-340. View Abstract

  44. Challenges in Acanthamoeba Keratitis: A Review. J Clin Med. 2021 Mar 01; 10(5). View Abstract

  45. Efficacy of cyanoacrylate tissue adhesive in the management of corneal thinning and perforation due to microbial keratitis. Ocul Surf. 2020 10; 18(4):795-800. View Abstract

  46. Efficacy and retention of silicone punctal plugs for treatment of dry eye in patients with and without ocular graft-versus-host-disease. Ocul Surf. 2020 10; 18(4):731-735. View Abstract

  47. Prevalence of Persistent Corneal Epithelial Defects in Chronic Ocular Graft-Versus-Host Disease. Am J Ophthalmol. 2020 10; 218:296-303. View Abstract

  48. Restoration of Regulatory T-Cell Function in Dry Eye Disease by Antagonizing Substance P/Neurokinin-1 Receptor. Am J Pathol. 2020 09; 190(9):1859-1866. View Abstract

  49. The role of Th17 immunity in chronic ocular surface disorders. Ocul Surf. 2021 01; 19:157-168. View Abstract

  50. Placoid choroidopathy after bilateral uncomplicated descemet's membrane endothelial keratoplasty. Am J Ophthalmol Case Rep. 2020 Mar; 17:100610. View Abstract

  51. Evaluation of signs and symptoms of ocular surface disease after intravitreal injection. Acta Ophthalmol. 2019 Dec; 97(8):e1154-e1156. View Abstract

  52. Methods for Assessing Corneal Opacity. Semin Ophthalmol. 2019; 34(4):205-210. View Abstract

  53. Thrombospondin-1 in ocular surface health and disease. Ocul Surf. 2019 07; 17(3):374-383. View Abstract

  54. Reduced Efficacy of Low-dose Topical Steroids in Dry Eye Disease Associated With Graft-versus-Host Disease. Am J Ophthalmol. 2018 06; 190:17-23. View Abstract

  55. Interleukin-6 neutralization prolongs corneal allograft survival. Curr Trends Immunol. 2018; 19:105-113. View Abstract

  56. Proangiogenic Function of T Cells in Corneal Transplantation. Transplantation. 2017 04; 101(4):778-785. View Abstract

  57. In Reply. J Glaucoma. 2017 03; 26(3):e135-e136. View Abstract

  58. T Cell-Derived Granulocyte-Macrophage Colony-Stimulating Factor Contributes to Dry Eye Disease Pathogenesis by Promoting CD11b+ Myeloid Cell Maturation and Migration. Invest Ophthalmol Vis Sci. 2017 02 01; 58(2):1330-1336. View Abstract

  59. Ocular Decompression Retinopathy After Uncomplicated Cataract Surgery in a Patient With a History of Narrow-Angle Glaucoma. J Glaucoma. 2017 Jan 24. View Abstract

  60. Immediately sequential bilateral cataract surgery: advantages and disadvantages. Curr Opin Ophthalmol. 2017 Jan; 28(1):81-86. View Abstract

  61. Tear film assessments for the diagnosis of dry eye. Curr Opin Allergy Clin Immunol. 2016 10; 16(5):487-91. View Abstract

  62. Ocular Decompression Retinopathy After Uncomplicated Cataract Surgery in a Patient With a History of Narrow-Angle Glaucoma. J Glaucoma. 2016 08; 25(8):e756-8. View Abstract

  63. A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease. Ophthalmology. 2016 07; 123(7):1449-57. View Abstract

  64. E-Selectin Mediates Immune Cell Trafficking in Corneal Transplantation. Transplantation. 2016 Apr; 100(4):772-80. View Abstract

  65. Effect of Penetrating Keratoplasty and Keratoprosthesis Implantation on the Posterior Segment of the Eye. Invest Ophthalmol Vis Sci. 2016 Apr; 57(4):1643-8. View Abstract

  66. In Vivo Expansion of Regulatory T Cells by Low-Dose Interleukin-2 Treatment Increases Allograft Survival in Corneal Transplantation. Transplantation. 2016 Mar; 100(3):525-32. View Abstract

  67. Graft Site Microenvironment Determines Dendritic Cell Trafficking Through the CCR7-CCL19/21 Axis. Invest Ophthalmol Vis Sci. 2016 Mar; 57(3):1457-67. View Abstract

  68. Dry Eye Disease After Refractive Surgery. Int Ophthalmol Clin. 2016; 56(2):101-10. View Abstract

  69. VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation. Transplantation. 2015 Apr; 99(4):678-86. View Abstract

  70. Reduced Corneal Endothelial Cell Density in Patients With Dry Eye Disease. Am J Ophthalmol. 2015 Jun; 159(6):1022-1026.e2. View Abstract

  71. Effects of corneal nerve density on the response to treatment in dry eye disease. Ophthalmology. 2015 Apr; 122(4):662-8. View Abstract

  72. Corneal inflammation after miniature keratoprosthesis implantation. Invest Ophthalmol Vis Sci. 2014 Dec 16; 56(1):185-9. View Abstract

  73. Extraorbital lacrimal gland excision: a reproducible model of severe aqueous tear-deficient dry eye disease. Cornea. 2014 Dec; 33(12):1336-41. View Abstract

  74. Mesenchymal stem cells home to inflamed ocular surface and suppress allosensitization in corneal transplantation. Invest Ophthalmol Vis Sci. 2014 Sep 16; 55(10):6631-8. View Abstract

  75. CCR7 is critical for the induction and maintenance of Th17 immunity in dry eye disease. Invest Ophthalmol Vis Sci. 2014 Aug 19; 55(9):5871-7. View Abstract

  76. Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival. Graefes Arch Clin Exp Ophthalmol. 2014 Nov; 252(11):1755-62. View Abstract

  77. A novel murine model for keratoprosthesis. Invest Ophthalmol Vis Sci. 2014 May 15; 55(6):3681-5. View Abstract

  78. Corneal Lymphatics: Role in Ocular Inflammation as Inducer and Responder of Adaptive Immunity. J Clin Cell Immunol. 2014; 5. View Abstract

  79. CCL-21 conditioned regulatory T cells induce allotolerance through enhanced homing to lymphoid tissue. J Immunol. 2014 Jan 15; 192(2):817-23. View Abstract

  80. The CCR6/CCL20 axis mediates Th17 cell migration to the ocular surface in dry eye disease. Invest Ophthalmol Vis Sci. 2013 Jun 12; 54(6):4081-91. View Abstract

  81. PDE4 inhibition suppresses IL-17-associated immunity in dry eye disease. Invest Ophthalmol Vis Sci. 2012 Jun 14; 53(7):3584-91. View Abstract
BESbswy